11.15.22 -- Needed: An AI Revolution In Rare Disease Trials

Quris has developed a treatment for Fragile-X syndrome, the most common inherited cause of autism and intellectual disabilities worldwide. Isaac Bentwich, M.D., the founder and CEO of Quris, believes the rare disease space, in general, is a difficult one to navigate.

This blog seeks to answer the question: how can team members be supported during key moments of their employee journeys, those moments that matter most to them, before they even have to ask?

Paper diaries may appear cheaper, but there are hidden costs that make a digital eCOA solution much more affordable in your clinical trial.

In this white paper, consider how far the field of imaging has recently come, as well as the latest innovations, and what lies ahead.

Despite the fast pace of medical innovation, the lack of consistency between technology systems managing these advancements ultimately inhibits research progress. Find out more in this blog.

In this brochure, read how wearable motion-sensing technology has been used for drug development research.

ePRO has proven to increase compliance, reduce patient burden, and, with Medrio’s seamless EDC integration, you can be sure your data is more accurate, complete, and secure.

As the industry leader in trial master file best practices, Phlexglobal understands the reasons why some companies fail inspections and why others consistently do well. Customers place their trust in Phlexglobal because of our proven mastery over the TMF-related questions and challenges they face every day.

IQVIA Complete Consent provides an easy, secure way to deliver highly engaging, regulatory compliant electronic consent for trials of all types.

Our collaboration makes it easier for life sciences organizations engaged in clinical trials to support better patient access.